HIFU

EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

Retrieved on: 
Wednesday, November 2, 2022
HIFU, Prostate cancer, Google Images, TMS, Laser, ESWL, Company, EDAP, Focal, Medical imaging

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY23

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Prostate cancer, Annual report, Risk, U.S. Securities and Exchange Commission, Focal, Centers for Medicare & Medicaid Services, HIFU, Google Images, APC, Hospital, Nasdaq, CMS, COVID-19, ESWL, OPPS, TMS, Adoption, Laser, Company, Medicare, Patient, EDAP, Health insurance, Medical imaging

LYON, France, November 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has released its final outpatient prospective payment system (OPPS) reimbursement rule for calendar year 2023 (CY23), which becomes effective on January 1st.

Key Points: 
  • For a hospital performing a Focal One HIFU prostate ablation on an outpatient basis, the final rule increases the reimbursement level to an Ambulatory Payment Classification (APC) level 6, as compared to APC level 5 currently.
  • This represents an increase of more than 90% over the current reimbursement level.
  • We view this as a very positive step forward for the prostate cancer patients who can benefit from this novel therapy.
  • Ryan Rhodes, Chief Executive Officer of EDAP US, stated, This final rule change is a significant development in achieving appropriate reimbursement for facilities offering their patients a precise treatment with Focal One HIFU.

Promaxo Announces Six System Sales in the Third Quarter 2022

Retrieved on: 
Tuesday, October 4, 2022
Urinary bladder, GLOBE, Hospital, Physician, Robotics, Urology Center of Westchester, Technology, Associate, American Urological Association, CEO, Pain, Infertility, FDA, Longitudinal wave, MRI, Karl, Urethra, Male, HIFU, Partnership, Kidney, Microsurgery, Erectile dysfunction, Sale, University, Patient, Exocrine gland, Diagnosis, Magnetic resonance imaging, Village, Scar, Prostate cancer, Cryosurgery, AI, Company, Awareness, Medical imaging, Pharmaceutical industry, Central Texas, Urology, Central Florida

OAKLAND, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, today announced the sale of six systems in the United States in the third quarter ending September 30, 2022.

Key Points: 
  • OAKLAND, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, today announced the sale of six systems in the United States in the third quarter ending September 30, 2022.
  • The system sales included both operating lease and revenue share agreements with physician practices in Florida, New Jersey, and Texas.
  • Promaxos single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo MRI system.
  • The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration

Retrieved on: 
Monday, September 26, 2022
Risk, COVID-19, TMS, Laser, Q&A, Company, Lithotripsy, EDAP, Focal, U.S. Securities and Exchange Commission, ESWL, Langham Hotel, London, Annual report, Nasdaq, Security (finance), Google Images, HIFU, Prostate cancer, Medical imaging

LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.

Key Points: 
  • LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.
  • Please join the company in-person or virtually as it hosts an event featuring:
    A Focal One Robotic focal HIFU introduction from EDAP's U.S. CEO
    A live Q&A session will follow the formal presentations.
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

Rhonda's Kiss Partners With Brooklyn Maimonides Health Cancer Center for "Legacy of Love" Fall 2022 Gala on September 7th

Retrieved on: 
Wednesday, September 7, 2022
Zero, Incontinence, Partnership, Patient, Breast cancer, CEO, Charles McCord, Cancer, The Dining Room, Research, Johnston Building (Charlotte, North Carolina), Oncology, Soho House, Beaux Arts, Disease, Man, Memory, Heart, Gala, Chair, NED, Health, Diagnosis, Legacy, Snug, Little, Ned Abraham, Education, Social, The, NEW, Rhonda, The NoMad, Surgeon, Club, Jojo, The Atrium, Kiss, AMA Foundation Leadership Award, Roswell Park Comprehensive Cancer Center, MCG, HIFU, Face, Pinot, New York Fashion Week, Skurnik Wines, Woman, Transport, Maimonides, Family, Radiology, Nightclub

NEW YORK, Sep. 6, 2022 /PRNewswire-PRWeb/ -- The Rhonda's Kiss 'Legacy of Love' gala will take place at the newly opened hotel and members club The Ned NoMad helmed by Richie Akiva in Manhattan, New York on September 7, 2022 ahead of New York Fashion Week, benefitting Maimonides Health. Rhonda's Kiss has partnered with Maimonides Health for their inaugural New York gala, with the annual event having taken place in Los Angeles since 2016. The 'Legacy of Love' Gala will be chaired by Executive Chairman Marc Stefanski, Film Producer/Actor Kyle Stefanski, Executive Director at Rhonda's Kiss, Film Director/Actor Danny A. Abeckaser, Global Hospitality Entrepreneur Richie Akiva, Film Producer Eustace Montgomery Hicks, and Midtown Equities President Michael Cayre.

Key Points: 
  • Rhonda's Kiss has partnered with Maimonides Health for their inaugural New York gala, with the annual event having taken place in Los Angeles since 2016.
  • The Gala will honor their legacies with the Legacy of Love gala and these special memorial tributes by Chair members.
  • Proceeds from the Rhonda's Kiss 'Legacy of Love' Gala will support non-medical services at the award-winning Maimonides Cancer Center in Brooklyn to fund their Patient Care Program.
  • For more information on the gala and to donate:
    Maimonides' nationally accredited award-winning Cancer Center is recognized for clinical excellence.

EDAP Reports Second Quarter 2022 Results

Retrieved on: 
Wednesday, August 24, 2022
Prostate cancer, Level 5, Technology, Centers for Medicare & Medicaid Services, OPPS, Distribution, American Urological Association, Total, USD, EDAP, Awareness, Optimism, APC, EUR, National Prostate Health Month, Investment, Center, Prospective payment system, Medicare, Nasdaq, ET, HIFU, Webcast, Review, Adoption, Tourism, Video game, Film, Cryptocurrency

Total revenue in the HIFU business for the second quarter 2022 was EUR 3.0 million (USD 3.2 million), an increase of 49.3% as compared to EUR 2.0 million (USD 2.4 million) for the second quarter of 2021.

Key Points: 
  • Total revenue in the HIFU business for the second quarter 2022 was EUR 3.0 million (USD 3.2 million), an increase of 49.3% as compared to EUR 2.0 million (USD 2.4 million) for the second quarter of 2021.
  • Total revenue in the LITHO business for the second quarter 2022 was EUR 3.6 million (USD 3.8 million), an increase of 55.7% from was EUR 2.3 million (USD 2.7 million) for the second quarter of 2021.
  • Total revenue in the Distribution business for the second quarter 2022 was EUR 7.6 million (USD 8.1 million), a 25.5% increase compared to EUR 6.1 million (USD 7.3 million) for the second quarter of 2021.
  • Operating loss for the second quarter of 2022 was EUR 0.4 million (USD 0.5 million), compared to an operating loss of EUR 0.4 million (USD 0.5 million) in the second quarter of 2021.

Global High Intensity Focused Ultrasound Market (2022 to 2027) - Featuring Hitachi, General Electric and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022
Medical Devices, Health, FDA, Pancreas, Liver, Woman, BPH, High-intensity focused ultrasound, Johnson & Johnson, Cancer, Industry, R, Breast, Prostate cancer, Growth, EDAP, Prevalence, Tissue, Research, International Prostate Symptom Score, Blood, FUS, Lymph, Man, Medtronic, COVID-19, Prostate, Urinary bladder, Lists of diseases, Hemostasis, Safety, Awareness, Kidney, Cavitation, Clinic, Aesthetics, General Electric, Heat, LUTS, Hitachi, American Institute for Cancer Research, Disease, Medical imaging, Pharmaceutical industry, HIFU

Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.

Key Points: 
  • Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.
  • As the COVID-19 pandemic progresses, the High-intensity focused ultrasound (HIFU) therapy industry has seen a growth drop.
  • Worldwide High-intensity Focused Ultrasound (HIFU) Therapy Market Size was US$ 269.3 Million in 2021:
    Based on modality, the High-Intensity Focused Ultrasound Therapy market is segmented into therapeutic ultrasound, hemostasis, others.
  • Major players operating in the HIFU therapy industry include Johnson & Johnson, Hitachi, Ltd, General Electric, Medtronic, Inc., Stryker, Koninklijke Philips, EDAP TMS S.A, Supersonic Imagine.

EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

Retrieved on: 
Wednesday, August 3, 2022
HIFU, Company, Google Images, EDAP, Laser, Prostate cancer, Focal, ESWL, TMS, Medical imaging

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

Promaxo Announces Two In-Office MRI Sales in US East Coast

Retrieved on: 
Wednesday, July 27, 2022
AI, MRI, Sale, Biopsy, Diagnosis, Urology, Specialization, GLOBE, Awareness, Longitudinal wave, Physician, Industry, Hospital, Â, CEO, Village, Associate, Prostate cancer, Software, Risk, Erectile dysfunction, Summit Medical Group, Technology, FDA, Company, Prostate, Cancer, Patient, Robotics, Cryosurgery, Infection, Benign prostatic hyperplasia, American Urological Association, HIFU, Cryotherapy, Medical imaging

Promaxos single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner.

Key Points: 
  • Promaxos single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner.
  • By addressing limitations of traditional MRI systems, we are actively pursuing a $3 billion market for in-office urology procedures and advancing point of care MRI enabled interventions.
  • Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform.
  • The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

New Piezoelectric Ultrasound Transducers for 360 Degree Ultrasonic Applications

Retrieved on: 
Tuesday, July 26, 2022
Mars mission, PIC, Neoplasm, Investment, NASA, POC, Industry, Research, Waterloo (blog post), Cytometry, IVD, Hertz, Therapy, Echolocation, Gas, Communication, Automation, HIFU, Electronic component, PI

AUBURN, Mass., July 26, 2022  /PRNewswire-PRWeb/ -- PI Ceramic, a global leader in the design and production of ultrasonic transducers, piezoelectric actuators and electro-ceramic mechanisms, offers a line of standard-size and miniaturized transducers for ultrasonic applications. Piezoelectric ultrasonic transducers can transmit and detect soundwaves up to very high frequencies in the Megahertz range. In medical applications, ultrasound is used for therapeutics, for tumors removal, for imaging, and also for blood flow monitoring. In industrial automation applications, contactless fluid metering of liquids and gases, and level detection systems are also based on ultrasound transducers. As for every-day life applications, most modern cars have piezoelectric ultrasound transducers built into their bumpers to help the drivers avoid collisions with nearby objects during parking maneuvers.

Key Points: 
  • AUBURN, Mass., July 26, 2022 /PRNewswire-PRWeb/ -- PI Ceramic, a global leader in the design and production of ultrasonic transducers, piezoelectric actuators and electro-ceramic mechanisms, offers a line of standard-size and miniaturized transducers for ultrasonic applications.
  • Piezoelectric ultrasonic transducers can transmit and detect soundwaves up to very high frequencies in the Megahertz range.
  • In industrial automation applications, contactless fluid metering of liquids and gases , and level detection systems are also based on ultrasound transducers.
  • Uses for electro-ceramic spherical transducers include medical high-intensity focused ultrasound (HIFU), therapeutic ultrasound, hydrophones, and sonar transducers.